In geriatric evaluation, some iadl (Katz) scale items are more predictive of efficacy and toxicity than ADL (Lawton) scale or Charlson Comorbidity Index in metastasic castration-resistant protate cancer (mCRPC) patients treated with cabazitaxel in a weekly schedule

Authors :: Begoña Mellado
Eva Fernandez Parra
Jose Angel Arranz
B. Pérez-Valderrama
María José Juan Fita
Susana Hernando Polo
Cristina Caballero Diaz
Urbano Anido Herranz
Montserrat Domenech
Daniel Castellano
Ovidio Fernandez Calvo
Maria Ochoa de Olza
Miguel Angel Climent Duran
Source :: Journal of Clinical Oncology. 37:176-176
Publication Year :: 2019
Publisher :: American Society of Clinical Oncology (ASCO), 2019.
Abstract: 176 Background: Cabazitaxel (CBZ) improves overall survival in mCRPC that progresses during or after docetaxel treatment. CABASEM is a phase II study to evaluate the efficacy and safety of a weekly schedule of CBZ for 'unfit' (ECOG2, previous neutropenic fever with docetaxel, or radiotherapy to

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Activities of daily living
business.industry
Cancer
Phases of clinical research
Castration resistant
medicine.disease
Docetaxel
Cabazitaxel
Internal medicine
Charlson comorbidity index
Toxicity
medicine
business
medicine.drug

Tools